SCHEMBL11228183

SCHEMBL11228183

O=C(O)c1cc(-c2ccccc2)cc(Cl)c1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C2 P52895 12/20 1.00
AKR1C1 Q04828 12/20 1.00
PTPN1 P18031 3/20 0.66
AKR1C4 P17516 2/20 0.64
AKR1C3 P42330 2/20 0.64
PTPN2 P17706 1/20 0.62
PTPN6 P29350 1/20 0.62
KDM4E B2RXH2 1/20 0.56
MEN1 O00255 1/20 0.56
ALDH1A1 P00352 1/20 0.56
MAPT P10636 1/20 0.56
PKM P14618 1/20 0.56
HPGD P15428 1/20 0.56
HTT P42858 1/20 0.56
KMT2A Q03164 1/20 0.56
HSD17B10 Q99714 1/20 0.56
FTO Q9C0B1 1/20 0.55
ACMSD Q8TDX5 3/20 0.55
HNF4A P41235 2/20 0.55
DHFR P00374 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27999624 0.86 PTPN1 (0.78) AKR1C2AKR1C1PTPN1AKR1C4AKR1C3
SCHEMBL6850839 0.83 AKR1C2 (0.71) AKR1C2AKR1C1PTPN1AKR1C4AKR1C3
SCHEMBL3564211 0.82 TTR (0.70) AKR1C2AKR1C1ALDH1A1HSD17B10FTO
SCHEMBL4833538 0.80 AKR1C2 (0.74) AKR1C2AKR1C1PTPN1AKR1C4AKR1C3
SCHEMBL18304655 0.80 AKR1C2 (0.67) AKR1C2AKR1C1PTPN1AKR1C4AKR1C3
SCHEMBL11693280 0.80 AKR1C2 (0.66) AKR1C2AKR1C1AKR1C4AKR1C3
SCHEMBL5437754 0.79 PTPN1 (1.00) AKR1C2AKR1C1PTPN1AKR1C4AKR1C3
SCHEMBL18319714 0.78 AKR1C2 (1.00) AKR1C2AKR1C1PTPN1AKR1C4AKR1C3
SCHEMBL6055013 0.78 AKR1C2 (1.00) AKR1C2AKR1C1PTPN1AKR1C4AKR1C3
SCHEMBL8046560 0.78 PTPN1 (0.66) AKR1C2AKR1C1PTPN1AKR1C4AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10702537-B2 Devices and methods of treating methamphetamine addiction and medical and behavioral consequences of methamphetamine use and of HIV infection BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2020-07-07 US disclosed
US-10561668-B1 Devices and methods of treating methamphetamine addiction and medical and behavioral consequences of methamphetamine use and of HIV infection BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY (US) 2020-02-18 US disclosed
US-20190224211-A1 DEVICES AND METHODS OF TREATING METHAMPHETAMINE ADDICTION AND MEDICAL AND BEHAVIORAL CONSEQUENCES OF METHAMPHETAMINE USE AND OF HIV INFECTION BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE 2019-07-25 US disclosed
US-10022383-B2 Devices and methods of treating methamphetamine addiction and medical and behavioral consequences of methamphetamine use and of HIV infection BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2018-07-17 US disclosed
US-20160367565-A1 DEVICES AND METHODS OF TREATING METHAMPHETAMINE ADDICTION AND MEDICAL AND BEHAVIORAL CONSEQUENCES OF METHAMPHETAMINE USE AND OF HIV INFECTION BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2016-12-22 US disclosed
US-4355070-A COLOR FORMER, DEVELOPER, HEAT FUSIBLE MATERIAL AND OIL ABSORPTIVE PIGMENT KANZAKI PAPER MANUFACTURING CO., LTD. (JP) 1982-10-19 US disclosed
US-4311758-A INORGANIC PIGMENTS IN THE COLOR DEVELOPER LAYER KANZAKI PAPER MANUFACTURING CO., LTD. (JP) 1982-01-19 US disclosed
US-4236732-A COLOR DEVELOPING LAYER CONTAINING PARTICLES OF A CHROMOGENIC MATERIAL, AN ACCEPTOR AND A HEAT FUSIBLE MATERIAL KANZAKI PAPER MANUFACTURING CO., LTD. (JP) 1980-12-02 US disclosed
US-4228222-A COLOR DEVELOPING LAYER INCLUDING WATER SOLUBLE RESIN AS BINDER KANZAKI PAPER MANUFACTURING CO., LTD. (JP) 1980-10-14 US disclosed
US-4168845-A Heat-sensitive record material KANZAKI PAPER MANUFACTURING CO., LTD. (JP) 1979-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10022383-B2 Devices and methods of treating methamphetamine addiction and medical and behavioral consequences of methamphetamine use and of HIV infection TSPO, SLC18A2, SLC18A3 AKR1C2 3197/4885AKR1C1 3135/4885PTPN1 4622/4885
US-10561668-B1 Devices and methods of treating methamphetamine addiction and medical and behavioral consequences of methamphetamine use and of HIV infection TSPO, SLC18A2, SLC18A3 AKR1C2 3197/4885AKR1C1 3135/4885PTPN1 4622/4885
US-20160367565-A1 DEVICES AND METHODS OF TREATING METHAMPHETAMINE ADDICTION AND MEDICAL AND BEHAVIORAL CONSEQUENCES OF METHAMPHETAMINE USE AND OF HIV INFECTION TSPO, SLC18A2, SLC18A3 AKR1C2 3197/4885AKR1C1 3135/4885PTPN1 4622/4885
US-10702537-B2 Devices and methods of treating methamphetamine addiction and medical and behavioral consequences of methamphetamine use and of HIV infection TSPO, SLC18A2, SLC18A3 AKR1C2 3197/4885AKR1C1 3135/4885PTPN1 4622/4885
US-20190224211-A1 DEVICES AND METHODS OF TREATING METHAMPHETAMINE ADDICTION AND MEDICAL AND BEHAVIORAL CONSEQUENCES OF METHAMPHETAMINE USE AND OF HIV INFECTION TSPO, SLC18A2, SLC18A3 AKR1C2 3197/4885AKR1C1 3135/4885PTPN1 4622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.